FOXO4-DRI vs KGLOW
FOXO4-DRI and KGLOW are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: FOXO4-DRI is 46-residue all-d retro-inverso peptide, while KGLOW is four-component dermal research blend — ghk-cu 50 mg / bpc-157 10 mg / tb-500 10 mg / kpv 10 mg (80 mg total) — different molecular classes with different handling consequences; they call for different primary diluents (sterile water (usp grade) versus bacteriostatic water (0.9% benzyl alcohol)); their leading degradation routes differ (deamidation at the asn-gly motif in the sequence for FOXO4-DRI, copper dissociation from the ghk-cu component at acidic ph or on chelator contact for KGLOW), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
FOXO4-DRI — origin
FOXO4-DRI was designed in the laboratory of Peter de Keizer (Erasmus University Medical Center) and published in Cell in 2017 (Baar et al.). It mimics the region of the transcription factor FOXO4 that binds p53, but is built from D-amino acids in reversed order — a retro-inverso design that keeps the side-chain layout while making the backbone unrecognisable to proteases. A cationic, arginine-rich tail derived from the HIV-TAT cell-penetrating sequence carries it into cells.
KGLOW — origin
KGLOW is GLOW with a fourth component added: KPV, a tripeptide (Lys-Pro-Val) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone. The other three amounts are unchanged — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg — with KPV at 10 mg bringing the vial to 80 mg. KPV is studied primarily for anti-inflammatory activity in preclinical models, notably retaining that property of the parent hormone without its pigmentation-related effects.
FOXO4-DRI research themes
The founding study showed that senescent cells rely on FOXO4 holding p53 in the nucleus. Interfering with that interaction caused p53 nuclear exclusion and intrinsic apoptosis selectively in senescent cells in culture (Baar et al., Cell 2017).
The same study examined doxorubicin-induced senescence, fast-ageing XpdTTD/TTD mice and naturally aged mice, reporting changes in fur density, fitness and renal markers.
Studied in hydrogen-peroxide-induced senescent TM3 Leydig cells and aged mice for effects on the testicular microenvironment (Zhang et al., Aging 2020).
At 25 µM in vitro it removed a large share of late-passage (senescent-enriched) human chondrocytes while sparing early-passage cells, without improving cartilage-forming capacity (Huang et al., Front Bioeng Biotechnol 2021).
KGLOW research themes
The majority component, with the deepest dermal research literature.
The addition that distinguishes KGLOW — studied for anti-inflammatory activity derived from alpha-MSH without pigmentation effects.
Two complementary tissue-repair mechanisms, unchanged from GLOW.
Adds an inflammation arm to the three repair-focused mechanisms in GLOW.
FOXO4-DRI handling
- Let the vial reach room temperature before opening.
- Add diluent gently down the vial wall and swirl; do not vortex.
- Use low-bind polypropylene rather than glass for dilutions — the cationic tail adsorbs to glass.
- Protect solutions from light.
KGLOW handling
- Never reconstitute in acidic diluent — copper dissociation from the GHK-Cu component is the primary risk.
- Keep EDTA and other chelators out of any buffer used with KGLOW.
- Treat colour as data: clear even blue is correct; pale or green is not.
- Protect from light and minimise headspace exposure for the TB-500 component.
- Scale diluent to the 80 mg fill — habitually adding 2 mL as though to a 10 mg vial gives a solution eight times more concentrated than intended.
Both third-party tested
Every Popular Peptides batch of FOXO4-DRI and KGLOW is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
FOXO4-DRI reference
Related comparisons
FOXO4-DRI and KGLOW are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.